Inclusion Criteria:~* Diagnosis of Stage 3 or Stage 4 Alzheimer's disease (AD) based on the 2018 National
Institute on Aging (NIA)-Alzheimer's Association (AA) Research Framework Criteria.~ * Mini-Mental State
Examination (MMSE) score of 20 to 28, inclusive, at Screening.~ * Blood-based biomarker results with a value
consistent with amyloid positron emission tomography (PET) positivity. The biomarker will be chosen by the
sponsor and described in the Laboratory Manual. Biomarker results will not be required for eligibility if the
participant has a positive Amyloid PET scan meeting the central reader criteria.~* Amyloid PET scan results
consistent with amyloid pathology.~* Stage B: Participants must have a study partner who spends a minimum
average of 10 hours per week with the participant.~
